Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
February 14, 2018 - The FDA announced the approval of Janssen Biotech’s Erleada (apalutamide), for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).
